Synergy Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SGYP)

$1.90 +0.04 (+2.15 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$1.90
Today's Range$1.77 - $1.90
52-Week Range$1.68 - $5.97
Volume5.05 million shs
Average Volume6.91 million shs
Market Capitalization$478.73 million
P/E Ratio-1.64
Dividend YieldN/A
Beta1.13

About Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. TRULANCE is designed to replicate the function of uroguanylin. Dolcanatide is being evaluated for inflammatory bowel disease (IBD). TRULANCE is approved in the United States under the trademark name TRULANCE, for the treatment of adults with chronic idiopathic constipation (CIC). In addition, it is developing TRULANCE for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Dolcanatide is designed to be an analog of uroguanylin with enhanced resistance to standard digestive breakdown by proteases in the intestine.

Receive SGYP News and Ratings via Email

Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:SGYP
CUSIP87163930
Phone+1-212-2970020

Debt

Debt-to-Equity Ratio-68.13%
Current Ratio4.26%
Quick Ratio3.88%

Price-To-Earnings

Trailing P/E Ratio-1.63793103448276
Forward P/E Ratio-1.84
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book9.05

Profitability

Trailing EPS($1.16)
Net Income$-198,600,000.00
Net Margins-975.86%
Return on Equity-941.37%
Return on Assets-156.39%

Miscellaneous

Employees116
Outstanding Shares246,660,000

Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.06. The biopharmaceutical company had revenue of $5.01 million for the quarter, compared to analyst estimates of $4.53 million. Synergy Pharmaceuticals had a negative return on equity of 941.37% and a negative net margin of 975.86%. During the same quarter in the prior year, the firm posted ($0.22) EPS. View Synergy Pharmaceuticals' Earnings History.

Where is Synergy Pharmaceuticals' stock going? Where will Synergy Pharmaceuticals' stock price be in 2018?

9 equities research analysts have issued 1 year target prices for Synergy Pharmaceuticals' stock. Their forecasts range from $2.50 to $15.00. On average, they expect Synergy Pharmaceuticals' share price to reach $8.94 in the next twelve months. View Analyst Ratings for Synergy Pharmaceuticals.

What are Wall Street analysts saying about Synergy Pharmaceuticals stock?

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (2/17/2018)
  • 2. Cantor Fitzgerald analysts commented, "As we predicted in a report published last week, SGYP disclosed that the cash balance at the end of January exceeded the $128 million level required to access $100 million from the CRG Term Loan Agreement." (2/1/2018)
  • 3. HC Wainwright analysts commented, "We note that the launch of Trulance appears to be progressing on multiple fronts, with the company having reached 66% of its targeted prescriber base and over 90% of the high-volume prescribers (deciles 8-10). According to QuintilesIMS data, as of mid-2017 over 12,600 Trulance prescriptions had been filled and total monthly prescription volume has increased on average over 182% month-over-month during that period. Over 32% of all high prescribers had written a Trulance prescription since the drug was launched earlier this year, with an average increase for all prescribers of approximately 140% month-over-month. Trulance achieved 6.8% new-to-brand prescription (NBRx) total market share and 12% NBRx market share among gastroenterologists. Importantly, about 55% of new Trulance prescriptions filled since launch were coming from new patients not previously on a branded prescription treatment and 45% were patients who converted from other branded prescription treatments." (8/10/2017)

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 76,502,450 shares, a drop of 4.9% from the January 12th total of 80,417,036 shares. Based on an average daily trading volume, of 8,996,015 shares, the short-interest ratio is presently 8.5 days. Currently, 31.1% of the company's shares are sold short.

Who are some of Synergy Pharmaceuticals' key competitors?

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the folowing people:

  • Gary S. Jacob Ph.D., Executive Chairman of the Board (Age 70)
  • Troy Hamilton, Chief Executive Officer, Director (Age 45)
  • Gary G. Gemignani, Chief Financial Officer, Executive Vice President (Age 52)
  • Marino Garcia, Executive Vice President, Chief Strategy Officer (Age 50)
  • Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer (Age 61)
  • Melvin K. Spigelman M.D., Lead Independent Director (Age 68)
  • Thomas H. Adams Jr. Ph.D., Independent Director (Age 74)
  • John P. Brancaccio CPA, Independent Director (Age 69)
  • Timothy S. Callahan, Independent Director (Age 46)
  • Richard J. Daly, Independent Director (Age 64)

Who owns Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.92%), PAULSON & COMPANY . INC. (1.78%), Deutsche Bank AG (0.88%), Geode Capital Management LLC (0.81%), Hikari Power Ltd (0.77%) and Bank of New York Mellon Corp (0.44%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Who sold Synergy Pharmaceuticals stock? Who is selling Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Cheyne Capital Management UK LLP, Alliancebernstein L.P., Deutsche Bank AG, Bank of New York Mellon Corp, Metropolitan Life Insurance Co. NY, Wells Fargo & Company MN and Bank of Montreal Can. View Insider Buying and Selling for Synergy Pharmaceuticals.

Who bought Synergy Pharmaceuticals stock? Who is buying Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Hikari Power Ltd, Granite Investment Partners LLC, Virtu Financial LLC, Schwab Charles Investment Management Inc., Malaga Cove Capital LLC, Teacher Retirement System of Texas and MetLife Investment Advisors LLC. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

How do I buy Synergy Pharmaceuticals stock?

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synergy Pharmaceuticals' stock price today?

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $1.90.

How big of a company is Synergy Pharmaceuticals?

Synergy Pharmaceuticals has a market capitalization of $478.73 million. The biopharmaceutical company earns $-198,600,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Synergy Pharmaceuticals employs 116 workers across the globe.

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 Lexington Ave Rm 2012, NEW YORK, NY 10170-2099, United States. The biopharmaceutical company can be reached via phone at +1-212-2970020 or via email at [email protected]


MarketBeat Community Rating for Synergy Pharmaceuticals (SGYP)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  508 (Thanks for Voting!)
Underperform Votes:  206 (Thanks for Voting!)
Total Votes:  714
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Synergy Pharmaceuticals (NASDAQ:SGYP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.802.78
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.94$8.94$8.40$10.47
Price Target Upside: 325.93% upside252.14% upside341.18% upside196.51% upside

Synergy Pharmaceuticals (NASDAQ:SGYP) Consensus Price Target History

Price Target History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ:SGYP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018HC WainwrightReiterated RatingBuy$7.00HighView Rating Details
2/1/2018Cantor FitzgeraldReiterated RatingBuyHighView Rating Details
1/22/2018OppenheimerReiterated RatingHoldHighView Rating Details
1/5/2018CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
1/5/2018CitigroupDowngradeMarket PerformHighView Rating Details
11/14/2017BTIG ResearchReiterated RatingBuy$7.00N/AView Rating Details
11/12/2017Canaccord GenuitySet Price TargetBuy$13.00N/AView Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy -> Buy$18.00 -> $15.00HighView Rating Details
3/2/2017GuggenheimReiterated RatingOutperform$10.00N/AView Rating Details
12/15/2016Roth CapitalReiterated RatingBuy$6.50N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Synergy Pharmaceuticals (NASDAQ:SGYP) Earnings History and Estimates Chart

Earnings by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ SGYP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.28)($0.22)$4.53 million$5.01 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.25)($0.33)$1.98 million$2.31 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.23)($0.30)$0.10 million$0.10 millionViewN/AView Earnings Details
3/1/2017Q4 2016($0.20)($0.31)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.22)($0.22)ViewN/AView Earnings Details
8/8/2016Q216($0.20)($0.23)ViewN/AView Earnings Details
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details
2/25/2016Q4 2015($0.25)($0.27)ViewN/AView Earnings Details
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details
8/9/2013Q2 2013($0.23)($0.13)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.17)($0.24)ViewN/AView Earnings Details
3/18/2013Q4 2012($0.15)($0.17)ViewN/AView Earnings Details
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.13)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.12)($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Synergy Pharmaceuticals (NASDAQ:SGYP) Earnings Estimates

2018 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.16)($0.16)($0.16)
Q2 20181($0.17)($0.17)($0.17)
Q3 20181($0.16)($0.16)($0.16)
Q4 20181($0.15)($0.15)($0.15)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Synergy Pharmaceuticals (NASDAQ:SGYP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 58.09%
Insider Trades by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)
Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals (NASDAQ SGYP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/10/2017Paulson & Co. Inc.Major ShareholderSell8,750,000$2.82$24,675,000.00View SEC Filing  
8/7/2017Paulson & Co. Inc.Major ShareholderSell26,287$3.77$99,101.99View SEC Filing  
5/26/2017Gary S JacobCEOBuy5,680$3.52$19,993.60402,679View SEC Filing  
5/26/2017John P BrancaccioDirectorBuy6,500$3.59$23,335.0030,444View SEC Filing  
11/4/2016Paulson & Co. Inc.Major ShareholderSell140,000$4.24$593,600.00View SEC Filing  
9/28/2016Paulson & Co. Inc.Major ShareholderSell54,300$5.69$308,967.00View SEC Filing  
9/19/2016John P BrancaccioDirectorSell2,518$5.76$14,503.6821,883View SEC Filing  
9/19/2016Paulson & Co. Inc.Major ShareholderSell3,473,713$5.61$19,487,529.93View SEC Filing  
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Synergy Pharmaceuticals (NASDAQ SGYP) News Headlines

Source:
DateHeadline
Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.Investor Alert: Kaplan Fox Announces Investigation Of Synergy Pharmaceuticals Inc.
www.prnewswire.com - February 24 at 3:49 PM
-$0.19 Earnings Per Share Expected for Synergy Pharmaceuticals Inc (SGYP) This Quarter-$0.19 Earnings Per Share Expected for Synergy Pharmaceuticals Inc (SGYP) This Quarter
www.americanbankingnews.com - February 24 at 9:26 AM
Safirstein Metcalf LLP Announces that a Class Action has been Filed Against Synergy Pharmaceuticals Inc - SGYPSafirstein Metcalf LLP Announces that a Class Action has been Filed Against Synergy Pharmaceuticals Inc - SGYP
feeds.benzinga.com - February 23 at 6:07 PM
IMPORTANT INVESTOR ALERT FOR ALL OWNERS OF SYNERGY PHARMACEUTICALS, INC.: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Synergy Pharmaceuticals, Inc.IMPORTANT INVESTOR ALERT FOR ALL OWNERS OF SYNERGY PHARMACEUTICALS, INC.: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Synergy Pharmaceuticals, Inc.
finance.yahoo.com - February 23 at 4:43 PM
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Synergy Pharmaceuticals Inc. ShareholdersKessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for Synergy Pharmaceuticals Inc. Shareholders
finance.yahoo.com - February 23 at 4:43 PM
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action LawsuitINVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
finance.yahoo.com - February 22 at 4:47 PM
Synergy Pharmaceuticals Inc (SGYP) Given Consensus Recommendation of "Hold" by BrokeragesSynergy Pharmaceuticals Inc (SGYP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 20 at 5:32 PM
INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.
finance.yahoo.com - February 20 at 4:40 PM
Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed against Synergy Pharmaceuticals Inc.Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed against Synergy Pharmaceuticals Inc.
finance.yahoo.com - February 20 at 4:40 PM
The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Synergy Pharmaceuticals Inc. (SGYP)The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Synergy Pharmaceuticals Inc. (SGYP)
finance.yahoo.com - February 20 at 4:40 PM
Synergy Pharmaceuticals (SGYP) Rating Increased to Sell at BidaskClubSynergy Pharmaceuticals (SGYP) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - February 18 at 1:00 PM
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.
finance.yahoo.com - February 17 at 4:45 PM
Zacks Investment Research Lowers Synergy Pharmaceuticals (SGYP) to HoldZacks Investment Research Lowers Synergy Pharmaceuticals (SGYP) to Hold
www.americanbankingnews.com - February 17 at 1:02 PM
Robbins Arroyo LLP: Synergy Pharmaceuticals Inc. (SGYP) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Synergy Pharmaceuticals Inc. (SGYP) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - February 17 at 8:52 AM
Synergy Pharma (SGYP) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowSynergy Pharma (SGYP) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 4:43 PM
SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc. - SGYPSHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc. - SGYP
finance.yahoo.com - February 16 at 4:43 PM
Zacks Investment Research Upgrades Synergy Pharmaceuticals (SGYP) to BuyZacks Investment Research Upgrades Synergy Pharmaceuticals (SGYP) to Buy
www.americanbankingnews.com - February 16 at 12:34 PM
SGYP INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Synergy Pharmaceuticals Inc. InvestorsSGYP INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Synergy Pharmaceuticals Inc. Investors
finance.yahoo.com - February 16 at 8:57 AM
SGYP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Synergy Pharmaceuticals Inc.SGYP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Synergy Pharmaceuticals Inc.
finance.yahoo.com - February 15 at 4:46 PM
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. - SGYPSHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. - SGYP
finance.yahoo.com - February 15 at 6:37 AM
Hagens Berman Alerts Synergy Pharmaceuticals Investors to the Securities Class Action Concerning Loan Disclosures and to the April 10, 2018 Lead Plaintiff DeadlineHagens Berman Alerts Synergy Pharmaceuticals Investors to the Securities Class Action Concerning Loan Disclosures and to the April 10, 2018 Lead Plaintiff Deadline
finance.yahoo.com - February 15 at 6:37 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Synergy Pharmaceuticals Inc.INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Synergy Pharmaceuticals Inc.
finance.yahoo.com - February 14 at 3:27 PM
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy ... - Business Wire (press release)EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy ... - Business Wire (press release)
www.businesswire.com - February 14 at 6:37 AM
Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Filed Against Synergy Pharmaceuticals Inc ... - PR Newswire (press release)Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Filed Against Synergy Pharmaceuticals Inc ... - PR Newswire (press release)
www.prnewswire.com - February 14 at 6:37 AM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Synergy Pharmaceuticals Inc. Investors (SGYP) - Business Wire (press release)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Synergy Pharmaceuticals Inc. Investors (SGYP) - Business Wire (press release)
www.businesswire.com - February 14 at 6:37 AM
Synergy Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Synergy Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - February 14 at 6:37 AM
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. – SGYPEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. – SGYP
finance.yahoo.com - February 14 at 6:37 AM
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Synergy Pharmaceuticals, Inc. (SGYP) and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Synergy Pharmaceuticals, Inc. (SGYP) and Encourages Investors to Contact the Firm
finance.yahoo.com - February 13 at 3:24 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Synergy Pharmaceuticals Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Synergy Pharmaceuticals Inc.
finance.yahoo.com - February 13 at 3:24 PM
Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Filed Against Synergy Pharmaceuticals Inc. - SGYPKessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Filed Against Synergy Pharmaceuticals Inc. - SGYP
finance.yahoo.com - February 13 at 3:24 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Synergy ... - PR Newswire (press release)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Synergy ... - PR Newswire (press release)
www.prnewswire.com - February 13 at 6:37 AM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) To Contact Brower Piven Before The Lead Plaintiff Deadline
feeds.benzinga.com - February 12 at 9:27 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Synergy Pharmaceuticals Inc. (SGYP) & Lead Plaintiff Deadline: April 10, 2018
finance.yahoo.com - February 12 at 3:25 PM
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Synergy Pharmaceuticals Inc. Investors (SGYP)Glancy Prongay & Murray LLP Commences Investigation on Behalf of Synergy Pharmaceuticals Inc. Investors (SGYP)
finance.yahoo.com - February 12 at 3:25 PM
Synergy Pharmaceuticals Inc (SGYP) Short Interest UpdateSynergy Pharmaceuticals Inc (SGYP) Short Interest Update
www.americanbankingnews.com - February 10 at 1:40 AM
WeissLaw LLP Files Class Action Lawsuit Against Synergy Pharmaceuticals Inc.WeissLaw LLP Files Class Action Lawsuit Against Synergy Pharmaceuticals Inc.
www.prnewswire.com - February 9 at 1:44 PM
Where Is Synergy Pharmaceuticals Inc Heading From Here? H.C. Wainwright Weighs InWhere Is Synergy Pharmaceuticals Inc Heading From Here? H.C. Wainwright Weighs In
finance.yahoo.com - February 6 at 3:24 PM
Synergy Pharmaceuticals (SGYP) Stock Rating Upgraded by Zacks Investment ResearchSynergy Pharmaceuticals (SGYP) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 6 at 1:56 PM
Synergy Pharmaceuticals (SGYP) Rating Lowered to Strong Sell at BidaskClubSynergy Pharmaceuticals (SGYP) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - February 6 at 6:52 AM
In The Spotlight: Synergy Pharma - Nasdaq.com - NasdaqIn The Spotlight: Synergy Pharma - Nasdaq.com - Nasdaq
www.nasdaq.com - February 5 at 3:24 PM
Biotech Forum Daily Digest For January 5th - Seeking AlphaBiotech Forum Daily Digest For January 5th - Seeking Alpha
seekingalpha.com - February 5 at 3:24 PM
Synergy Pharmaceuticals (SGYP) Rating Lowered to Hold at Zacks Investment ResearchSynergy Pharmaceuticals (SGYP) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 3 at 1:28 PM
Synergy Pharmaceuticals: Lack Of Transparency Hurts Stock ... - Seeking AlphaSynergy Pharmaceuticals: Lack Of Transparency Hurts Stock ... - Seeking Alpha
seekingalpha.com - February 3 at 6:34 AM
Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed ... - Seeking AlphaYour Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed ... - Seeking Alpha
seekingalpha.com - February 2 at 3:26 PM
Synergy Pharma: Lack Of Transparency Hurts Stock - Seeking AlphaSynergy Pharma: Lack Of Transparency Hurts Stock - Seeking Alpha
seekingalpha.com - February 2 at 3:26 PM
Synergy Clears Another Hurdle: Now What? - Seeking AlphaSynergy Clears Another Hurdle: Now What? - Seeking Alpha
seekingalpha.com - February 2 at 3:26 PM
Synergy Pharmaceuticals (SGYP) Given "Buy" Rating at Cantor FitzgeraldSynergy Pharmaceuticals (SGYP) Given "Buy" Rating at Cantor Fitzgerald
www.americanbankingnews.com - February 1 at 3:54 PM
Synergy Pharmaceuticals Achieves Cash Balance Requirement to Access Additional Capital - Business Wire (press release)Synergy Pharmaceuticals Achieves Cash Balance Requirement to Access Additional Capital - Business Wire (press release)
www.businesswire.com - February 1 at 3:24 PM
HC Wainwright Reaffirms Buy Rating for Synergy Pharmaceuticals (SGYP)HC Wainwright Reaffirms Buy Rating for Synergy Pharmaceuticals (SGYP)
www.americanbankingnews.com - February 1 at 1:52 PM
Synergy Pharmaceuticals (SGYP) Downgraded to Sell at BidaskClubSynergy Pharmaceuticals (SGYP) Downgraded to Sell at BidaskClub
www.americanbankingnews.com - January 31 at 9:52 PM

SEC Filings

Synergy Pharmaceuticals (NASDAQ:SGYP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Synergy Pharmaceuticals (NASDAQ:SGYP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Synergy Pharmaceuticals (NASDAQ SGYP) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.